Novel mechanism for protein delivery in breast cancer therapy: A public health perspective
Full Text (PDF)
Taiwo Temitope Ogunjobi 1 * , Ngozi Maryann Nebolisa 2 , Rufus Oluwagbemileke Ajayi 3 , Morenikeji Ibilola Euba 4 , Adnan Musa 5 , Abdul-Hanan Saani Inusah 6 , Femi Adedayo 7 , Ojoisimi Franca Jamgbadi 8 , Akinwunmi Rapheal Afuape 9 , Adeleye Adegboyega Edema 10 , Stephen Ajuluchukwu Echesi 11 , Daniel Ebubechi Obasi 12 , Sulaimon Olajuwon Abdul 13 , Saheed Adegbola Adeyanju 14
More Detail
1 Department of Biochemistry, Faculty of Basic Medical Sciences, Ladoke Akintola University of Technology, Ogbomosho, Oyo State, NIGERIA2 Department of Pharmacy, Faculty of Pharceutical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, NIGERIA3 Department of Public Health, University of Illinois at Springfield, Springfield, IL, USA4 Department of Nutritional Science, University of Calabria, Arcavacata, ITALY5 Department of Epidemiology, First Moscow State Medical University, Moscow, RUSSIA6 School of Medicine, University for Development Studies, Tamale, GHANA7 Department of Computer Science, Imo State University, Owerri, Imo State, NIGERIA8 Department of Pharmacy, Faculty of Pharmacy, University of Benin, Benin, Edo State, NIGERIA9 Department of Biology, Faculty of College of Science and Technology, North Carolina Agriculture and Technical University, Greensboro, NC, USA10 Department of Biochemistry, Faculty of Basic Medical Science, Olabisi Onabanjo University, Ago Iwoye, Ogun State, NIGERIA11 Department of Microbiology, Faculty of Biological Sciences, University of Port Harcourt, Port Harcourt, NIGERIA12 Department of Medicine and Surgery, University of Ibadan, Ibadan, Oyo State, NIGERIA13 Department of Pharmacy, Faculty of Pharmacy, Olabisi Onabanjo University, Ago Iwoye, Ogun State, NIGERIA14 Department of Bioinformatics, School of Health and Life Science, Teesside University, Middlesbrough, UK* Corresponding Author
Abstract
Breast cancer is still a major global public health concern, requiring novel treatment strategies that might enhance results and minimize adverse effects. From the perspective of public health, this review highlights the potential of innovative routes for protein delivery in breast cancer treatment to change therapeutic approaches. We investigate sophisticated protein delivery methods, such as ligand-directed targeting, nanoparticle-based carriers, and bioengineered proteins, and evaluate their efficacy in maximizing medication specificity and reducing toxicity through a methodical review of recent literature. According to our research, the distribution of therapeutic proteins to breast cancer cells is greatly enhanced by these innovative delivery methods, which increases treatment efficacy while lowering systemic exposure and side effects. Specifically, biological barriers have been demonstrated to be achievable by targeted delivery systems, which also target the tumor microenvironment. This allows for the localized release of therapeutic medicines at the tumor site. These developments have significant implications, including the possibility of more individualized and minimally invasive breast cancer therapy choices. These innovative delivery methods can improve patient quality of life and adherence to treatment plans by lessening the adverse effects of conventional chemotherapy, which will improve overall treatment outcomes. Looking forward, it will be crucial to conduct more research and development on protein delivery systems. Future directions ought to concentrate on investigating combination medicines, refining delivery systems for practical usage, and carrying out extensive clinical trials to assess efficacy and safety. This study highlights the role of public health in promoting access to these innovations and enhancing cancer care, underscoring the significance of incorporating novel protein delivery systems into treatment options for breast cancer.
License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article Type: Review Article
EUR J SUSTAIN DEV RES, Volume 9, Issue 2, 2025, Article No: em0283
https://doi.org/10.29333/ejosdr/16054
Publication date: 01 Apr 2025
Online publication date: 25 Feb 2025
Article Views: 228
Article Downloads: 71
Open Access References How to cite this articleReferences
- Abd Ellah, N. H., Tawfeek, H. M., John, J., & Hetta, H. F. (2019). Nanomedicine as a future therapeutic approach for hepatitis C virus. Nanomedicine, 14(11), 1471-1491. https://doi.org/10.2217/nnm-2018-0348
- Adegboyega, A., Aroh, A., Voigts, K., & Jennifer, H. (2019). Regular mammography screening among African American (AA) women: Qualitative application of the PEN-3 framework. Journal of Transcultural Nursing, 30(5), 444-452. https://doi.org/10.1177/1043659618803146
- Agaronnik, N. D., El-Jawahri, A., & Iezzoni, L. I. (2022). Implications of physical access barriers for breast cancer diagnosis and treatment in women with mobility disability. Journal of Disability Policy Studies, 33(1), 46-54. https://doi.org/10.1177/10442073211010124
- Aguiar Jr, P. N., Adashek, J. J., Roitberg, F., Noia Barreto, C. M., Del Giglio, A., & Lopes Jr, G. L. (2019). In the era of cost-effectiveness analysis, affordability is a limiting factor for patients’ access to innovative cancer treatments. Value in Health Regional Issues, 20, 47-50. https://doi.org/10.1016/j.vhri.2018.12.003
- Akinyemiju, T., Chen, Q., Wilson, L. E., Previs, R. A., Joshi, A., Liang, M., Pisu, M., Ward, K. C., Berchuck, A., Schymura, M. J., & Huang, B. (2023). Healthcare access domains mediate racial disparities in ovarian cancer treatment quality in a US patient cohort: A structural equation modelling analysis. Cancer Epidemiology, Biomarkers & Prevention, 32(1), 74-81. https://doi.org/10.1158/1055-9965.epi-22-0650
- Al-Mansoori, L., Elsinga, P., & Goda, S. K. (2021). Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. Biomedecine & Pharmacotherapy, 144, Article 112260. https://doi.org/10.1016/j.biopha.2021.112260
- Amreddy, N., Babu, A., Muralidharan, R., Panneerselvam, J., Srivastava, A., Ahmed, R., Mehta, M., Munshi, A., & Ramesh, R. (2018). Recent advances in nanoparticle-based cancer drug and gene delivery. In Advances in cancer research (pp. 115-170). Elsevier. https://doi.org/10.1016/bs.acr.2017.11.003
- Ausi, Y., Santoso, P., Sunjaya, D., & Barliana, M. I. (2021). Between curing and torturing: Burden of adverse reaction in drug-resistant tuberculosis therapy. Patient Preference and Adherence, 15, 2597-2607. https://doi.org/10.2147/ppa.s333111
- Balderrama, F., Schwartz, L. J., & Longo, C. J. (2020). When are pharmaceuticals priced fairly? An alternative risk-sharing model for pharmaceutical pricing. Health Care Analysis: HCA: Journal of Health Philosophy and Policy, 28(2), 121-136. https://doi.org/10.1007/s10728-020-00394-x
- Bashraheel, S. S., Domling, A., & Goda, S. K. (2020). Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomedecine & Pharmacotherapy, 125, Article 110009. https://doi.org/10.1016/j.biopha.2020.110009
- Basu, P., Zhang, L., Hariprasad, R., Carvalho, A., & Barchuk, A. (2020). A pragmatic approach to tackle the rising burden of breast cancer through prevention & early detection in countries “in transition.” The Indian Journal of Medical Research, 152(4), Article 343. https://doi.org/10.4103/ijmr.ijmr_1868_19
- Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018). Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. Journal of Controlled Release, 277, 1-13. https://doi.org/10.1016/j.jconrel.2018.02.040
- Berman, R., Davies, A., Cooksley, T., Gralla, R., Carter, L., Darlington, E., Scotté, F., & Higham, C. (2020). Supportive care: An indispensable component of modern oncology. Clinical Oncology, 32(11), 781-788. https://doi.org/10.1016/j.clon.2020.07.020
- Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022). Nanoparticle-based delivery systems for vaccines. Vaccines, 10(11), Article 1946. https://doi.org/10.3390/vaccines10111946
- Chang, Y., Yao, S., Chen, Y., Huang, J., Wu, A., Zhang, M., Xu, F., Li, F., & Huang, Y. (2019). Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy. Nanoscale, 11(2), 611-621. https://doi.org/10.1039/c8nr08951e
- Chehade, M. J., Yadav, L., Kopansky-Giles, D., Merolli, M., Palmer, E., Jayatilaka, A., & Slater, H. (2020). Innovations to improve access to musculoskeletal care. Best Practice & Research Clinical Rheumatology, 34(5), Article 101559. https://doi.org/10.1016/j.berh.2020.101559
- Chen, Q., Chen, M., & Liu, Z. (2019). Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. Chemical Society Reviews, 48(22), 5506-5526. https://doi.org/10.1039/c9cs00271e
- Cheng, L., Yang, L., Meng, F., & Zhong, Z. (2018). Protein nanotherapeutics as an emerging modality for cancer therapy. Advanced Healthcare Materials, 7(20). https://doi.org/10.1002/adhm.201800685
- Cong, X., Chen, J., & Xu, R. (2022). Recent progress in bio-responsive drug delivery systems for tumor therapy. Frontiers in Bioengineering and Biotechnology, 10. https://doi.org/10.3389/fbioe.2022.916952
- Coughlin, S. S. (2019). Social determinants of breast cancer risk, stage, and survival. Breast Cancer Research and Treatment, 177(3), 537-548. https://doi.org/10.1007/s10549-019-05340-7
- Cruz, E., & Kayser, V. (2019). Synthesis and enhanced cellular uptake in vitro of anti-HER2 multifunctional gold nanoparticles. Cancers, 11(6), Article 870. https://doi.org/10.3390/cancers11060870
- De Maria, C., Di Pietro, L., Díaz Lantada, A., Madete, J., Makobore, P. N., Mridha, M., Ravizza, A., Torop, J., & Ahluwalia, A. (2018). Safe innovation: On medical device legislation in Europe and Africa. Health Policy and Technology, 7(2), 156-165. https://doi.org/10.1016/j.hlpt.2018.01.012
- Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., & Makvandi, P. (2021). Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. Nano Today, 38, Article 101119. https://doi.org/10.1016/j.nantod.2021.101119
- Emami, F., Vatanara, A., Park, E., & Na, D. (2018). Drying technologies for the stability and bioavailability of biopharmaceuticals. Pharmaceutics, 10(3), Article 131. https://doi.org/10.3390/pharmaceutics10030131
- Essa, D., Kondiah, P. P. D., Choonara, Y. E., & Pillay, V. (2020). The design of poly(lactide-co-glycolide) nanocarriers for medical applications. Frontiers in Bioengineering and Biotechnology, 8. https://doi.org/10.3389/fbioe.2020.00048
- Fayzullin, A., Bakulina, A., Mikaelyan, K., Shekhter, A., & Guller, A. (2021). Implantable drug delivery systems and foreign body reaction: Traversing the current clinical landscape. Bioengineering, 8(12), Article 205. https://doi.org/10.3390/bioengineering8120205
- Gakunga, R., Kinyanjui, A., Ali, Z., Ochieng’, E., Gikaara, N., Maluni, F., Wata, D., Kyeng’, M., Korir, A., & Subramanian, S. (2019). Identifying barriers and facilitators to breast cancer early detection and subsequent treatment engagement in Kenya: A qualitative approach. The Oncologist, 24(12), 1549-1556. https://doi.org/10.1634/theoncologist.2019-0257
- Garbayo, E., Pascual-Gil, S., Rodríguez-Nogales, C., Saludas, L., Estella-Hermoso de Mendoza, A., & Blanco-Prieto, M. J. (2020). Nanomedicine and drug delivery systems in cancer and regenerative medicine. Nanomedicine and Nanobiotechnology, 12(5), Article e1637. https://doi.org/10.1002/wnan.1637
- Ghione, S., Mabrouk, N., Paul, C., Bettaieb, A., & Plenchette, S. (2020). Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment. Biochemical Pharmacology, 176, Article 113855. https://doi.org/10.1016/j.bcp.2020.113855
- Gutierrez, C., McEvoy, C., Munshi, L., Stephens, R. S., Detsky, M. E., Nates, J. L., & Pastores, S. M. (2020). Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Critical Care Medicine, 48(1), 10-21. https://doi.org/10.1097/ccm.0000000000004087
- Hatting, M., Tavares, C. D. J., Sharabi, K., Rines, A. K., & Puigserver, P. (2018). Insulin regulation of gluconeogenesis. Annals of the New York Academy of Sciences, 1411(1), 21-35. https://doi.org/10.1111/nyas.13435
- Haymond, A., Davis, J. B., & Espina, V. (2019). Proteomics for cancer drug design. Expert Review of Proteomics, 16(8), 647-664. https://doi.org/10.1080/14789450.2019.1650025
- Heer, E., Harper, A., Escandor, N., Sung, H., McCormack, V., & Fidler-Benaoudia, M. M. (2020). Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. The Lancet Global Health, 8(8), e1027-e1037. https://doi.org/10.1016/s2214-109x(20)30215-1
- Hellowell, M. (2018). Public private partnerships and the quality and efficiency of healthcare services. In Public-private partnerships in health (pp. 1-13). Springer. https://doi.org/10.1007/978-3-319-69563-1_1
- Hess, A. S., & Abd-Elsayed, A. (2019). Components of clinical trials. In Pain (pp. 83-85). Springer. https://doi.org/10.1007/978-3-319-99124-5_21
- Hu, D., Zhang, W., Tang, J., Zhou, Z., Liu, X., & Shen, Y. (2021). Improving safety of cancer immunotherapy via delivery technology. Biomaterials, 265, Article 120407. https://doi.org/10.1016/j.biomaterials.2020.120407
- Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018). Protein nanoparticles: Promising platforms for drug delivery applications. ACS Biomaterials Science & Engineering, 4(12), 3939-3961. https://doi.org/10.1021/acsbiomaterials.8b01098
- Kalidasan, V., & Theva Das, K. (2024). Advancing precision medicine with gene and cell therapy in Malaysia: Ethical, legal, and social implications. Human Gene Therapy, 35(1-2), 9-25. https://doi.org/10.1089/hum.2023.139
- Kasztura, M., Richard, A., Bempong, N.-E., Loncar, D., & Flahault, A. (2019). Cost-effectiveness of precision medicine: A scoping review. International Journal of Public Health, 64(9), 1261-1271. https://doi.org/10.1007/s00038-019-01298-x
- Kazibwe, J., Tran, P. B., & Annerstedt, K. S. (2021). The household financial burden of non-communicable diseases in low- and middle-income countries: A systematic review. Health Research Policy and Systems, 19(1). https://doi.org/10.1186/s12961-021-00732-y
- Kennedy, L. B., & Salama, A. K. S. (2020). A review of cancer immunotherapy toxicity. CA: A Cancer Journal for Clinicians, 70(2), 86-104. https://doi.org/10.3322/caac.21596
- Kintzing, J. R., Filsinger Interrante, M. V., & Cochran, J. R. (2016). Emerging strategies for developing next-generation protein therapeutics for cancer treatment. Trends in Pharmacological Sciences, 37(12), 993-1008. https://doi.org/10.1016/j.tips.2016.10.005
- Kopp, W. (2019). How western diet and lifestyle drive the pandemic of obesity and civilization diseases. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 12, 2221-2236. https://doi.org/10.2147/dmso.s216791
- Kretzmann, J. A., Luther, D. C., Evans, C. W., Jeon, T., Jerome, W., Gopalakrishnan, S., Lee, Y.-W., Norret, M., Iyer, K. S., & Rotello, V. M. (2021). Regulation of proteins to the cytosol using delivery systems with engineered polymer architecture. Journal of the American Chemical Society, 143(12), 4758-4765. https://doi.org/10.1021/jacs.1c00258
- Large, D. E., Soucy, J. R., Hebert, J., & Auguste, D. T. (2019). Advances in receptor-mediated, tumor-targeted drug delivery. Advanced Therapeutics, 2(1). https://doi.org/10.1002/adtp.201800091
- Lee, S. W. L., Paoletti, C., Campisi, M., Osaki, T., Adriani, G., Kamm, R. D., Mattu, C., & Chiono, V. (2019). MicroRNA delivery through nanoparticles. Journal of Controlled Release: Official Journal of the Controlled Release Society, 313, 80-95. https://doi.org/10.1016/j.jconrel.2019.10.007
- Li, N., Deng, Y., Zhou, L., Tian, T., Yang, S., Wu, Y., Zheng, Y., Zhai, Z., Hao, Q., Song, D., Zhang, D., Kang, H., & Dai, Z. (2019). Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: Results from the global burden of disease study 2017. Journal of Hematology & Oncology, 12(1). https://doi.org/10.1186/s13045-019-0828-0
- Lima, S. M., Kehm, R. D., & Terry, M. B. (2021). Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. eClinicalMedicine, 38, Article 100985. https://doi.org/10.1016/j.eclinm.2021.100985
- Ling, S. P., Ming, L. C., Dhaliwal, J. S., Gupta, M., Ardianto, C., Goh, K. W., Hussain, Z., & Shafqat, N. (2022). Role of immunotherapy in the treatment of cancer: A systematic review. Cancers, 14(21), Article 5205. https://doi.org/10.3390/cancers14215205
- Liu, X., Wu, F., Ji, Y., & Yin, L. (2019). Recent advances in anti-cancer protein/peptide delivery. Bioconjugate Chemistry, 30(2), 305-324. https://doi.org/10.1021/acs.bioconjchem.8b00750
- Low, S.-K., & Nakamura, Y. (2019). The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. Japanese Journal of Clinical Oncology, 49(7), 596-603. https://doi.org/10.1093/jjco/hyz073
- Manavitehrani, I., Fathi, A., Schindeler, A., & Dehghani, F. (2018). Sustained protein release from a core-shell drug carrier system comprised of mesoporous nanoparticles and an injectable hydrogel. Macromolecular Bioscience, 18(12). https://doi.org/10.1002/mabi.201800201
- Mandal, A., Pal, D., Agrahari, V., Trinh, H. M., Joseph, M., & Mitra, A. K. (2018). Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. Advanced Drug Delivery Reviews, 126, 67-95. https://doi.org/10.1016/j.addr.2018.01.008
- Mansour, A., Romani, M., Acharya, A. B., Rahman, B., Verron, E., & Badran, Z. (2023). Drug delivery systems in regenerative medicine: An updated review. Pharmaceutics, 15(2), Article 695. https://doi.org/10.3390/pharmaceutics15020695
- Meng, L.-X., Ren, Q., Meng, Q., Zheng, Y.-X., He, M.-L., Sun, S.-Y., Ding, Z.-J., Li, B.-C., & Wang, H.-Y. (2018). Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer. Artificial Cells, Nanomedicine, and Biotechnology, 46(sup3), 556-563. https://doi.org/10.1080/21691401.2018.1501380
- Mériade, L., & Rochette, C. (2021). Integrated care pathway for breast cancer: A relational and geographical approach. Social Science & Medicine, 270, Article 113658. https://doi.org/10.1016/j.socscimed.2020.113658
- Mirza, Z., & Karim, S. (2021). Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. Seminars in Cancer Biology, 69, 226-237. https://doi.org/10.1016/j.semcancer.2019.10.020
- Moore, S., Leung, B., Bates, A., & Ho, C. (2018). Social isolation: Impact on treatment and survival in patients with advanced cancer. Journal of Clinical Oncology, 36(34_suppl), 156-156. https://doi.org/10.1200/jco.2018.36.34_suppl.156
- Morain, S. R., Weinfurt, K., Bollinger, J., Geller, G., Mathews, D. J. H., & Sugarman, J. (2020). Ethics and collateral findings in pragmatic clinical trials. The American Journal of Bioethics, 20(1), 6-18. https://doi.org/10.1080/15265161.2020.1689031
- Muhamad, N., Plengsuriyakarn, T., & Na-Bangchang, K. (2018). Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review. International Journal of Nanomedicine, 13, 3921-3935. https://doi.org/10.2147/ijn.s165210
- Murtuza, A., Bulbul, A., Shen, J. P., Keshavarzian, P., Woodward, B. D., Lopez-Diaz, F. J., Lippman, S. M., & Husain, H. (2019). Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Research, 79(4), 689-698. https://doi.org/10.1158/0008-5472.can-18-1281
- Nayyar, S., Chakole, S., Taksande, A. B., Prasad, R., Munjewar, P. K., & Wanjari, M. B. (2023). From awareness to action: A review of efforts to reduce disparities in breast cancer screening. Cureus, 15(6), Article e40674. https://doi.org/10.7759/cureus.40674
- Nielsen, D. L., Kümler, I., Palshof, J. A. E., & Andersson, M. (2013). Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast, 22(1), 1-12. https://doi.org/10.1016/j.breast.2012.09.008
- Papakonstantinou, T., & Kolettis, T. M. (2020). Investigational therapies and patients’ autonomy. Canadian Journal of Bioethics, 3(3), 115-117. https://doi.org/10.7202/1073786ar
- Papathanasiou, M. M., & Kontoravdi, C. (2020). Engineering challenges in therapeutic protein product and process design. Current Opinion in Chemical Engineering, 27, 81-88. https://doi.org/10.1016/j.coche.2019.11.010
- Ponce-Chazarri, L., Ponce-Blandón, J. A., Immordino, P., Giordano, A., & Morales, F. (2023). Barriers to breast cancer-screening adherence in vulnerable populations. Cancers, 15(3), Article 604. https://doi.org/10.3390/cancers15030604
- Radanovic, I., Klarenbeek, N., Rissmann, R., Groeneveld, G. J., van Brummelen, E. M. J., Moerland, M., & Bosch, J. J. (2022). Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.954806
- Rainey, L., van der Waal, D., Jervaeus, A., Wengström, Y., Evans, D. G., Donnelly, L. S., & Broeders, M. J. M. (2018). Are we ready for the challenge of implementing risk-based breast cancer screening and primary prevention? Breast, 39, 24-32. https://doi.org/10.1016/j.breast.2018.02.029
- Ranganathan, K., Singh, P., Raghavendran, K., Wilkins, E. G., Hamill, J. B., Aliu, O., Newman, L. A., Hutton, D., & Momoh, A. O. (2021). The global macroeconomic burden of breast cancer: Implications for oncologic surgery. Annals of Surgery, 274(6), 1067-1072. https://doi.org/10.1097/sla.0000000000003662
- Ribba, B., Boetsch, C., Nayak, T., Grimm, H. P., Charo, J., Evers, S., Klein, C., Tessier, J., Charoin, J. E., Phipps, A., Pisa, P., & Teichgräber, V. (2018). Prediction of the optimal dosing regimen using a mathematical model of tumor uptake for immunocytokine-based cancer immunotherapy. Clinical Cancer Research, 24(14), 3325-3333. https://doi.org/10.1158/1078-0432.ccr-17-2953
- Rodríguez-Nava, C., Ortuño-Pineda, C., Illades-Aguiar, B., Flores-Alfaro, E., Leyva-Vázquez, M. A., Parra-Rojas, I., del Moral-Hernández, O., Vences-Velázquez, A., Cortés-Sarabia, K., & del Carmen Alarcón-Romero, L. (2023). Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer. Biomedicines, 11(6), Article 1610. https://doi.org/10.3390/biomedicines11061610
- Scaletti, F., Hardie, J., Lee, Y.-W., Luther, D. C., Ray, M., & Rotello, V. M. (2018). Protein delivery into cells using inorganic nanoparticle-protein supramolecular assemblies. Chemical Society Reviews, 47(10), 3421-3432. https://doi.org/10.1039/c8cs00008e
- Schirrmacher, V. (2018). From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. International Journal of Oncology, 54(2), 407-419. https://doi.org/10.3892/ijo.2018.4661
- Schwartz, D. B., Barrocas, A., Annetta, M. G., Stratton, K., McGinnis, C., Hardy, G., Wong, T., Arenas, D., Turon-Findley, M. P., Kliger, R. G., Corkins, K. G., Mirtallo, J., Amagai, T., Guenter, P., & ASPEN International Clinical Ethics Position Paper Update Workgroup. (2021). Ethical aspects of artificially administered nutrition and hydration: An ASPEN position paper. Nutrition in Clinical Practice, 36(2), 254-267. https://doi.org/10.1002/ncp.10633
- Seidi, K., Neubauer, H. A., Moriggl, R., Jahanban-Esfahlan, R., & Javaheri, T. (2018). Tumor target amplification: Implications for nano drug delivery systems. Journal of Controlled Release, 275, 142-161. https://doi.org/10.1016/j.jconrel.2018.02.020
- Seidu, T. A., Kutoka, P. T., Asante, D. O., Farooq, M. A., Alolga, R. N., & Bo, W. (2022). Functionalization of nanoparticulate drug delivery systems and its influence in cancer therapy. Pharmaceutics, 14(5), Article 1113. https://doi.org/10.3390/pharmaceutics14051113
- Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018). Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduction and Targeted Therapy, 3(1). https://doi.org/10.1038/s41392-017-0004-3
- Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., De, P., Krie, A., Piccioni, D. E., Miller, V. A., Ross, J. S., Benson, A., Webster, J., Stephens, P. J., Lee, J. J., Fanta, P. T., Lippman, S. M., Leyland-Jones, B., & Kurzrock, R. (2019). Molecular profiling of cancer patients enables personalized combination therapy: The I-PREDICT study. Nature Medicine, 25(5), 744-750. https://doi.org/10.1038/s41591-019-0407-5
- Sokolenko, A. P., & Imyanitov, E. N. (2018). Molecular diagnostics in clinical oncology. Frontiers in Molecular Biosciences, 5. https://doi.org/10.3389/fmolb.2018.00076
- Souho, T., Lamboni, L., Xiao, L., & Yang, G. (2018). Cancer hallmarks and malignancy features: Gateway for improved targeted drug delivery. Biotechnology Advances, 36(7), 1928-1945. https://doi.org/10.1016/j.biotechadv.2018.08.001
- Stahlschmidt, R., Ferracini, A. C., de Souza, C. M., de Medeiros, L. M., Juliato, C. R. T., & Mazzola, P. G. (2019). Adherence and quality of life in women with breast cancer being treated with oral hormone therapy. Supportive Care in Cancer, 27(10), 3799-3804. https://doi.org/10.1007/s00520-019-04671-x
- Stern, A. D., Chen, J. L., Ouellet, M., Trusheim, M. R., El-Kilani, Z., Jessup, A., & Berndt, E. R. (2021). Biosimilars and follow-on products in the United States: Adoption, prices, and users. Health Affairs, 40(6), 989-999. https://doi.org/10.1377/hlthaff.2020.02239
- Sur, D., Havasi, A., Cainap, C., Samasca, G., Burz, C., Balacescu, O., Lupan, I., Deleanu, D., & Irimie, A. (2020). Chimeric antigen receptor T-cell therapy for colorectal cancer. Journal of Clinical Medicine, 9(1), Article 182. https://doi.org/10.3390/jcm9010182
- Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020). Tolerant/persister cancer cells and the path to resistance to targeted therapy. Cells, 9(12), Article 2601. https://doi.org/10.3390/cells9122601
- Tandon, P. K., & Kakkis, E. D. (2021). The multi-domain responder index: A novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases. Orphanet Journal of Rare Diseases, 16(1). https://doi.org/10.1186/s13023-021-01805-5
- Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021). Strategies for delivering therapeutics across the blood-brain barrier. Nature Reviews. Drug Discovery, 20(5), 362-383. https://doi.org/10.1038/s41573-021-00139-y
- Thakur, A., Huang, M., & Lum, L. G. (2018). Bispecific antibody based therapeutics: Strengths and challenges. Blood Reviews, 32(4), 339-347. https://doi.org/10.1016/j.blre.2018.02.004
- Thakur, N., Thakur, S., Chatterjee, S., Das, J., & Sil, P. C. (2020). Nanoparticles as smart carriers for enhanced cancer immunotherapy. Frontiers in Chemistry, 8. https://doi.org/10.3389/fchem.2020.597806
- Thomas, J. A., Miller, E. R., & Ward, P. R. (2022). Lifestyle interventions through participatory research: A mixed-methods systematic review of alcohol and other breast cancer behavioural risk factors. International Journal of Environmental Research and Public Health, 19(2), Article 980. https://doi.org/10.3390/ijerph19020980
- Tibensky, M., Jakubechova, J., Altanerova, U., Pastorakova, A., Rychly, B., Baciak, L., Mravec, B., & Altaner, C. (2022). Gene-directed enzyme/prodrug therapy of rat brain tumor mediated by human mesenchymal stem cell suicide gene extracellular vesicles in vitro and in vivo. Cancers, 14(3), Article 735. https://doi.org/10.3390/cancers14030735
- Tolba, R., Meselhy, E., & Elnagar, I. H. (2019). Global disparities in access to pain relief. In Pain (pp. 1185-1189). Springer. https://doi.org/10.1007/978-3-319-99124-5_252
- Tong, Q., Qiu, N., Ji, J., Ye, L., & Zhai, G. (2020). Research progress in bioinspired drug delivery systems. Expert Opinion on Drug Delivery, 17(9), 1269-1288. https://doi.org/10.1080/17425247.2020.1783235
- Tu, Y., Dong, Y., Wang, K., Shen, S., Yuan, Y., & Wang, J. (2020). Intercellular delivery of bioorthogonal chemical receptors for enhanced tumor targeting and penetration. Biomaterials, 259, Article 120298. https://doi.org/10.1016/j.biomaterials.2020.120298
- Ullgren, H., Tsitsi, T., Papastavrou, E., & Charalambous, A. (2018). How family caregivers of cancer patients manage symptoms at home: A systematic review. International Journal of Nursing Studies, 85, 68-79. https://doi.org/10.1016/j.ijnurstu.2018.05.004
- van der Laan, H. P., Van den Bosch, L., Schuit, E., Steenbakkers, R. J. H. M., van der Schaaf, A., & Langendijk, J. A. (2021). Impact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer. Radiotherapy and Oncology, 160, 47-53. https://doi.org/10.1016/j.radonc.2021.04.011
- Wang, J., Wang, Z., Yu, J., Kahkoska, A. R., Buse, J. B., & Gu, Z. (2020). Glucose-responsive insulin and delivery systems: Innovation and translation. Advanced Materials, 32(13), Article 1902004. https://doi.org/10.1002/adma.201902004
- Wang, Z., Deng, X., Ding, J., Zhou, W., Zheng, X., & Tang, G. (2018). Mechanisms of drug release in pH-sensitive micelles for tumour targeted drug delivery system: A review. International Journal of Pharmaceutics, 535(1-2), 253-260. https://doi.org/10.1016/j.ijpharm.2017.11.003
- Wu, C., Wang, C., Zheng, Y., Zheng, Y., Liu, Z., Xu, K., & Zhong, W. (2021). Triple enzyme-regulated molecular hydrogels for carrier-free delivery of lonidamine. Advanced Functional Materials, 31(42). https://doi.org/10.1002/adfm.202104418
- Xing, H., & Meng, L.-H. (2020). CRISPR-cas9: A powerful tool towards precision medicine in cancer treatment. Acta Pharmacologica Sinica, 41(5), 583-587. https://doi.org/10.1038/s41401-019-0322-9
- Yadav, A., Singh, S., Sohi, H., & Dang, S. (2021). Advances in delivery of chemotherapeutic agents for cancer treatment. AAPS PharmSciTech, 23(1). https://doi.org/10.1208/s12249-021-02174-9
- Yamaguchi, A., Anami, Y., Ha, S. Y. Y., Roeder, T. J., Xiong, W., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021). Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. Bioorganic & Medicinal Chemistry, 32, Article 116013. https://doi.org/10.1016/j.bmc.2021.116013
- Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in Molecular Biosciences, 7. https://doi.org/10.3389/fmolb.2020.00193
- Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H. (2019). Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers, 11(5), Article 640. https://doi.org/10.3390/cancers11050640
- Yu, H., Ning, N., Meng, X., Chittasupho, C., Jiang, L., & Zhao, Y. (2022). Sequential drug delivery in targeted cancer therapy. Pharmaceutics, 14(3), Article 573. https://doi.org/10.3390/pharmaceutics14030573
- Yu, J., Wang, Y., Zhou, S., Li, J., Wang, J., Chi, D., Wang, X., Lin, G., He, Z., & Wang, Y. (2020). Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy. Acta Pharmaceutica Sinica B, 10(9), 1730-1740. https://doi.org/10.1016/j.apsb.2020.04.011
- Zhang, X., Luukkonen, L. M., Eissler, C. L., Crowley, V. M., Yamashita, Y., Schafroth, M. A., Kikuchi, S., Weinstein, D. S., Symons, K. T., Nordin, B. E., Rodriguez, J. L., Wucherpfennig, T. G., Bauer, L. G., Dix, M. M., Stamos, D., Kinsella, T. M., Simon, G. M., Baltgalvis, K. A., & Cravatt, B. F. (2021). DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras. Journal of the American Chemical Society, 143(13), 5141-5149. https://doi.org/10.1021/jacs.1c00990
- Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020). Targeting strategies for tissue-specific drug delivery. Cell, 181(1), 151-167. https://doi.org/10.1016/j.cell.2020.02.001
- Zheng, Z., Han, X., Zhao, J., Banegas, M. P., Tucker-Seeley, R., Rai, A., Fedewa, S. A., Song, W., Jemal, A., & Yabroff, K. R. (2020). Financial hardship, healthcare utilization, and health among U.S. cancer survivors. American Journal of Preventive Medicine, 59(1), 68-78. https://doi.org/10.1016/j.amepre.2020.02.016
- Zou, P., Tang, R., & Luo, M. (2020). Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis. International Immunopharmacology, 78, Article 106050. https://doi.org/10.1016/j.intimp.2019.106050
How to cite this article
APA
Ogunjobi, T. T., Nebolisa, N. M., Ajayi, R. O., Euba, M. I., Musa, A., Inusah, A.-H. S., Adedayo, F., Jamgbadi, O. F., Afuape, A. R., Edema, A. A., Echesi, S. A., Obasi, D. E., Abdul, S. O., & Adeyanju, S. A. (2025). Novel mechanism for protein delivery in breast cancer therapy: A public health perspective. European Journal of Sustainable Development Research, 9(2), em0283. https://doi.org/10.29333/ejosdr/16054
Vancouver
Ogunjobi TT, Nebolisa NM, Ajayi RO, Euba MI, Musa A, Inusah AHS, et al. Novel mechanism for protein delivery in breast cancer therapy: A public health perspective. EUR J SUSTAIN DEV RES. 2025;9(2):em0283. https://doi.org/10.29333/ejosdr/16054
AMA
Ogunjobi TT, Nebolisa NM, Ajayi RO, et al. Novel mechanism for protein delivery in breast cancer therapy: A public health perspective. EUR J SUSTAIN DEV RES. 2025;9(2), em0283. https://doi.org/10.29333/ejosdr/16054
Chicago
Ogunjobi, Taiwo Temitope, Ngozi Maryann Nebolisa, Rufus Oluwagbemileke Ajayi, Morenikeji Ibilola Euba, Adnan Musa, Abdul-Hanan Saani Inusah, Femi Adedayo, Ojoisimi Franca Jamgbadi, Akinwunmi Rapheal Afuape, Adeleye Adegboyega Edema, Stephen Ajuluchukwu Echesi, Daniel Ebubechi Obasi, Sulaimon Olajuwon Abdul, and Saheed Adegbola Adeyanju. "Novel mechanism for protein delivery in breast cancer therapy: A public health perspective". European Journal of Sustainable Development Research 2025 9 no. 2 (2025): em0283. https://doi.org/10.29333/ejosdr/16054
Harvard
Ogunjobi, T. T., Nebolisa, N. M., Ajayi, R. O., Euba, M. I., Musa, A., Inusah, A.-H. S., . . . Adeyanju, S. A. (2025). Novel mechanism for protein delivery in breast cancer therapy: A public health perspective. European Journal of Sustainable Development Research, 9(2), em0283. https://doi.org/10.29333/ejosdr/16054
MLA
Ogunjobi, Taiwo Temitope et al. "Novel mechanism for protein delivery in breast cancer therapy: A public health perspective". European Journal of Sustainable Development Research, vol. 9, no. 2, 2025, em0283. https://doi.org/10.29333/ejosdr/16054